Pacer Advisors Inc. Sells 97,337 Shares of Supernus Pharmaceuticals, Inc. $SUPN

Pacer Advisors Inc. decreased its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 33.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 190,894 shares of the specialty pharmaceutical company’s stock after selling 97,337 shares during the quarter. Pacer Advisors Inc. owned approximately 0.34% of Supernus Pharmaceuticals worth $9,123,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SUPN. USA Financial Formulas bought a new position in shares of Supernus Pharmaceuticals in the third quarter valued at about $50,000. EverSource Wealth Advisors LLC acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at about $51,000. Raymond James Financial Inc. acquired a new position in Supernus Pharmaceuticals in the 2nd quarter valued at about $55,000. Osaic Holdings Inc. raised its holdings in Supernus Pharmaceuticals by 211.5% in the 2nd quarter. Osaic Holdings Inc. now owns 1,956 shares of the specialty pharmaceutical company’s stock valued at $63,000 after acquiring an additional 1,328 shares during the period. Finally, GAMMA Investing LLC lifted its position in Supernus Pharmaceuticals by 116.7% during the second quarter. GAMMA Investing LLC now owns 2,861 shares of the specialty pharmaceutical company’s stock worth $90,000 after acquiring an additional 1,541 shares during the last quarter.

Insider Activity

In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 710 shares of the company’s stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the sale, the vice president owned 14,508 shares of the company’s stock, valued at approximately $644,735.52. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Jack A. Khattar sold 59,900 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $50.57, for a total value of $3,029,143.00. Following the completion of the transaction, the chief executive officer directly owned 1,206,578 shares of the company’s stock, valued at approximately $61,016,649.46. This trade represents a 4.73% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 80,610 shares of company stock valued at $4,068,895. 8.80% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several research firms have recently commented on SUPN. Bank of America initiated coverage on Supernus Pharmaceuticals in a research report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 target price on the stock. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $46.00 to $63.00 and gave the company an “overweight” rating in a report on Tuesday, September 30th. TD Cowen increased their price objective on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the stock a “buy” rating in a research report on Thursday, October 23rd. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Monday, December 22nd. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $61.60.

Supernus Pharmaceuticals Price Performance

SUPN stock opened at $51.57 on Monday. The company has a 50 day simple moving average of $48.50 and a 200 day simple moving average of $43.17. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -151.67, a P/E/G ratio of 0.62 and a beta of 0.72. Supernus Pharmaceuticals, Inc. has a 1 year low of $29.16 and a 1 year high of $57.65.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing analysts’ consensus estimates of $0.82 by ($0.36). Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The company had revenue of $170.00 million during the quarter, compared to analyst estimates of $175.82 million. During the same quarter in the prior year, the business earned $0.69 EPS. The business’s quarterly revenue was up 9.3% on a year-over-year basis. On average, equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current fiscal year.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.